← Back

Symbiotix Biotherapies Announces License Agreement with Harvard University

BOSTON, MA, March 21, 2018Symbiotix Biotherapies, Inc. (“Symbiotix”), a pioneering venture-backed microbiome company developing novel molecular therapeutics based on the human microbiome, today announced that it has entered into a license agreement with Harvard University. Under the agreement, Symbiotix gains access to a portfolio of intellectual property developed in the laboratory of Dennis Kasper, M.D., William Ellery Channing Professor of Medicine and Professor of Microbiology and Immunobiology at Harvard Medical School.

Drawing on aspects of Dr. Kasper’s earlier research at Brigham & Women’s Hospital, Symbiotix developed Reglemers™, a new class of molecular therapeutics that modulate regulatory T cell (TREG) activity, providing a new therapeutic approach to protection against autoimmune and inflammatory diseases. The license from Harvard now provides additional compositions and methods that may enable improvements to that approach.

“We are extraordinarily pleased to expand our extensive intellectual property portfolio with this license agreement,” said Nader Yaghoubi, M.D., Ph.D., President and Chief Executive Officer of Symbiotix. “Symbiotix has steadily built the leading intellectual property portfolio in the microbiome sector, which now includes license agreements with four academic institutions, and includes issued composition-of-matter patents protecting our lead program.”

Dr. Kasper is a Scientific Co-Founder of Symbiotix Biotherapies, Inc.

About Symbiotix Biotherapies, Inc.

Symbiotix Biotherapies, Inc. is a pioneering venture-backed microbiome company founded on the basis of over two decades of research at Brigham & Women’s Hospital, Harvard Medical School, California Institute of Technology and Dartmouth College.  Symbiotix is developing a novel class of TREG-modulating therapeutics based on molecules derived from the human microbiome. As one of the earliest companies in the microbiome sector, the science behind our lead program has been described in over 100 scientific publications, represents the most well studied microbiome-derived molecule to date, and is now protected by issued composition-of-matter patents.  Symbiotix is dedicated to delivering first-in-class oral agents that improve the lives of patients with inflammatory bowel disease (IBD), multiple sclerosis (MS) and other serious immune-mediated diseases. For more information, please visit www.symbiotix-bio.com.

Source: Symbiotix Biotherapies, Inc.

Media Contact:
Sharon Correia
LaVoieHealthScience
scorreia@lavoiehealthscience.com